Myriad Genetics, Inc.
MYGN
Market Cap$592.69M
Close$
$-8.81
229.8% downside
Current Fair Value
229.8% downsideOvervalued by 229.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $592.69 Million |
|---|---|
| Enterprise Value | $677.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.41 |
| Beta | 1.9 |
| Outstanding Shares | 92,500,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.49 |
|---|---|
| PEG | -0.19 |
| Price to Sales | 0.75 |
| Price to Book Ratio | 1.7 |
| Enterprise Value to Revenue | 0.81 |
| Enterprise Value to EBIT | -1.64 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 0.41 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...